Hypofractionated Radiotherapy Does Not Increase Acute Toxicity in Large-breasted Women: Results from a Prospectively Collected Series
Overview
Authors
Affiliations
Background And Purpose: To compare the acute toxicity of hypofractionated whole breast radiotherapy (HypoRT) to conventionally fractionated radiotherapy (ConvRT) in large-breasted women with early stage disease.
Materials And Methods: Women with breast volume>1500 cm, body mass index>30 kg/m, or separation>25 cm treated with HypoRT or ConvRT from 2005 through 2010 were identified from a prospective database and included in the analysis. Acute toxicity was scored for each treated breast.
Results: Ninety-two patients were treated to 96 breasts. The median body mass index was 33 kg/m and median breast volume was 1932 cm for the ConvRT group compared with 32.4 kg/m and 1825 cm for the HypoRT group. Maximum acute skin toxicity consisted of focal moist desquamation in 26% and 11% of the ConvRT and HypoRT patients, respectively (P=0.002). Breast volume was the only patient factor significantly associated with moist desquamation on multivariable analysis (P=0.01). Among those with a breast volume >2500 cm, focal moist desquamation occurred in 40.7% (11/27) compared with 11.1% (7/63) in patients with breast volume <2500 cm (P=0.002).
Conclusions: Among obese and large-breasted women, there was no increase in acute skin toxicity with the use of HypoRT. HypoRT should be considered in obese and large-breasted women when advanced planning techniques are used.
Wu Z, Hou L, Li C, Li X, Li Y Breast Cancer (Dove Med Press). 2024; 16:423-432.
PMID: 39099624 PMC: 11297561. DOI: 10.2147/BCTT.S471901.
Bruand M, Salleron J, Guihard S, Crety C, Liem X, Pasquier D BMC Cancer. 2022; 22(1):1318.
PMID: 36526987 PMC: 9755801. DOI: 10.1186/s12885-022-10402-z.
Xiao A, Jutzy J, Hubert G, Edens M, Washington M, Hasan Y J Appl Clin Med Phys. 2020; 21(12):146-154.
PMID: 33124774 PMC: 7769386. DOI: 10.1002/acm2.13080.
Ratosa I, Jenko A, Oblak I Radiol Oncol. 2018; 52(3):233-244.
PMID: 30210048 PMC: 6137355. DOI: 10.2478/raon-2018-0026.
Lazzari G, Terlizzi A, Della Vittoria Scarpati G, Perri F, De Chiara V, Turi B Onco Targets Ther. 2017; 10:1835-1842.
PMID: 28392704 PMC: 5373827. DOI: 10.2147/OTT.S127833.